Definium reports positive Phase 3 results for DT120 ODT in GAD, FDA breakthrough status in MDD
The company posted two positive Phase 3 anxiety studies, an MDD breakthrough designation, and roughly $1.05 billion in cash as of September 30, 2026.
SEC filing